{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T22:18:29Z","timestamp":1726438709519},"reference-count":34,"publisher":"American Society for Microbiology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Developing an effective anthrax vaccine that can induce a rapid and sustained immune response is a priority for the prevention of bioterrorism-associated anthrax infection. Here, we developed a recombinant replication-deficient adenovirus serotype 5-based vaccine expressing the humanized protective antigen (Ad5-PAopt). A single intramuscular injection of Ad5-PAopt resulted in rapid and robust humoral and cellular immune responses in Fisher 344 rats. Animals intramuscularly inoculated with a single dose of 10<jats:sup>8<\/jats:sup>infectious units of Ad5-PAopt achieved 100% protection from challenge with 10 times the 50% lethal dose (LD<jats:sub>50<\/jats:sub>) of anthrax lethal toxin 7 days after vaccination. Although preexisting intranasally induced immunity to Ad5 slightly weakened the humoral and cellular immune responses to Ad5-PAopt via intramuscular inoculation, 100% protection was achieved 15 days after vaccination in Fisher 344 rats. The protective efficacy conferred by intramuscular vaccination in the presence of preexisting intranasally induced immunity was significantly better than that of intranasal delivery of Ad5-PAopt and intramuscular injection with recombinant PA and aluminum adjuvant without preexisting immunity. As natural Ad5 infection often occurs via the mucosal route, the work here largely illuminates that intramuscular inoculation with Ad5-PAopt can overcome the negative effects of immunity induced by prior adenovirus infection and represents an efficient approach for protecting against emerging anthrax.<\/jats:p>","DOI":"10.1128\/cvi.00560-13","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T02:02:34Z","timestamp":1386208954000},"page":"156-164","source":"Crossref","is-referenced-by-count":9,"title":["Intramuscular Delivery of Adenovirus Serotype 5 Vector Expressing Humanized Protective Antigen Induces Rapid Protection against Anthrax That May Bypass Intranasally Originated Preexisting Adenovirus Immunity"],"prefix":"10.1128","volume":"21","author":[{"given":"Shipo","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoqiong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2013,12,4]]},"reference":[{"key":"key20180919073720_B1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1128\/AAC.00706-06","article-title":"Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis","volume":"51","author":"Scorpio","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"key20180919073720_B2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","author":"Friedlander","year":"1993","journal-title":"J. Infect. Dis."},{"key":"key20180919073720_B3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0897190012442351","article-title":"Bioterrorism: toxins as weapons","volume":"25","author":"Anderson","year":"2012","journal-title":"J. Pharm. Pract."},{"key":"key20180919073720_B4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4103\/0975-7406.68499","article-title":"Biological warfare agents","volume":"2","author":"Thavaselvam","year":"2010","journal-title":"J. Pharm. Bioallied Sci."},{"key":"key20180919073720_B5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey","volume":"54","author":"Henderson","year":"1956","journal-title":"J. Hyg. (Lond.)"},{"key":"key20180919073720_B6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.mam.2009.08.006","article-title":"Anthrax vaccination strategies","volume":"30","author":"Cybulski","year":"2009","journal-title":"Mol. Aspects Med."},{"key":"key20180919073720_B7","doi-asserted-by":"publisher","first-page":"D28","DOI":"10.1016\/j.vaccine.2009.08.102","article-title":"Advances in the development of next-generation anthrax vaccines","volume":"27","author":"Friedlander","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073720_B8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1086\/523578","article-title":"Vaccines: countering anthrax: vaccines and immunoglobulins","volume":"46","author":"Grabenstein","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"key20180919073720_B9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/JB.85.1.230-236.1963","article-title":"Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man","volume":"85","author":"Puziss","year":"1963","journal-title":"J. Bacteriol."},{"key":"key20180919073720_B10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1586\/14760584.5.4.417","article-title":"Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine","volume":"5","author":"Keitel","year":"2006","journal-title":"Expert Rev. Vaccines"},{"key":"key20180919073720_B11","first-page":"1","article-title":"Viral vectors: a look back and ahead on gene transfer technology","volume":"36","author":"Vannucci","year":"2013","journal-title":"New Microbiol."},{"key":"key20180919073720_B12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1586\/erv.11.141","article-title":"Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases","volume":"10","author":"Zhang","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"key20180919073720_B13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"Ledgerwood","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073720_B14","doi-asserted-by":"publisher","first-page":"7777","DOI":"10.1073\/pnas.89.16.7777","article-title":"Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model","volume":"89","author":"Natuk","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073720_B15","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1016\/j.vaccine.2005.11.046","article-title":"De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses","volume":"24","author":"Wang","year":"2006","journal-title":"Vaccine"},{"key":"key20180919073720_B16","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1517\/14712590903307388","article-title":"Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors","volume":"9","author":"Seregin","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"key20180919073720_B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"key20180919073720_B18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1743-422X-9-111","article-title":"Prediction and identification of mouse cytotoxic T lymphocyte epitopes in Ebola virus glycoproteins","volume":"9","author":"Wu","year":"2012","journal-title":"Virol. J."},{"key":"key20180919073720_B19","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1016\/j.vaccine.2011.03.042","article-title":"Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China","volume":"29","author":"Sun","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073720_B20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge","volume":"4","author":"Fay","year":"2012","journal-title":"Sci. Transl. Med"},{"key":"key20180919073720_B21","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"key20180919073720_B22","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J. Immunol."},{"key":"key20180919073720_B23","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.vaccine.2010.12.087","article-title":"Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF","volume":"29","author":"Krause","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073720_B24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"key20180919073720_B25","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1016\/j.vaccine.2012.09.058","article-title":"Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform","volume":"30","author":"Gabitzsch","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073720_B26","doi-asserted-by":"publisher","first-page":"10780","DOI":"10.1128\/JVI.77.20.10780-10789.2003","article-title":"Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier","volume":"77","author":"Xiang","year":"2003","journal-title":"J. Virol."},{"key":"key20180919073720_B27","doi-asserted-by":"publisher","first-page":"e3548","DOI":"10.1371\/journal.pone.0003548","article-title":"Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice","volume":"3","author":"Croyle","year":"2008","journal-title":"PLoS One"},{"key":"key20180919073720_B28","doi-asserted-by":"publisher","first-page":"18091","DOI":"10.1073\/pnas.1013083107","article-title":"Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities","volume":"107","author":"Merkel","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073720_B29","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1128\/JVI.02864-12","article-title":"Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates","volume":"87","author":"Richardson","year":"2013","journal-title":"J. Virol."},{"key":"key20180919073720_B30","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1089\/104303403322542310","article-title":"Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen","volume":"14","author":"Tan","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"key20180919073720_B31","doi-asserted-by":"publisher","first-page":"6885","DOI":"10.1128\/IAI.73.10.6885-6891.2005","article-title":"Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity","volume":"73","author":"Hashimoto","year":"2005","journal-title":"Infect. Immun."},{"key":"key20180919073720_B32","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1128\/IAI.74.2.1009-1015.2006","article-title":"Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4","volume":"74","author":"McConnell","year":"2006","journal-title":"Infect. Immun."},{"key":"key20180919073720_B33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.mt.6300034","article-title":"Adenovirus-based prime-boost immunization for rapid vaccination against anthrax","volume":"15","author":"McConnell","year":"2007","journal-title":"Mol. Ther."},{"key":"key20180919073720_B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CVI.00280-12","article-title":"An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen","volume":"20","author":"Zhang","year":"2013","journal-title":"Clin. Vaccine Immunol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00560-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:50:21Z","timestamp":1627591821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00560-13"}},"subtitle":[],"editor":[{"given":"D. L.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,4]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,29]]},"published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1128\/CVI.00560-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00560-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"type":"print","value":"1556-6811"},{"type":"electronic","value":"1556-679X"}],"subject":[],"published":{"date-parts":[[2013,12,4]]}}}